Search research articles
Contact Us
Filters
Showing results (541-550 of 652) with videos related to
Page
of 66
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation
Antonio Palumbo, S Vincent Rajkumar, Jesus F San Miguel, et al.
Haematologica
|
October 4, 2015
European Myeloma Network guidelines for the management of multiple myeloma-related complications
Evangelos Terpos, Martina Kleber, Monika Engelhardt, et al.
Haematologica
|
April 16, 2016
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Katja C Weisel, Meletios A Dimopoulos, Philippe Moreau, et al.
Seminars in Hematology
|
May 16, 2025
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors
Jorge J Castillo, Francesco Autore, Neil L Berinstein, et al.
Seminars in Hematology
|
May 22, 2025
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathy
Shirley D'Sa, Jahanzaib Khwaja, Signy Chow, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 2, 2011
Prognostication of the high-risk WM patient
Efstathios Kastritis, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, et al.
Blood Advances
|
October 25, 2019
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone
Efstathios Kastritis, Ioanna Dialoupi, Maria Gavriatopoulou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 4, 2023
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
BMC Medicine
|
February 2, 2011
A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study
Christos A Papadimitriou, Pavlos Papakostas, Maria Karina, et al.
Hemasphere
|
August 29, 2025
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network
Grigoris Gerotziafas, Despina Fotiou, Inger Nijhof, et al.
Page
of 66
Search research articles
Search
Showing results (541-550 of 652) with videos related to
Sort By:
Page
of 66
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation
Antonio Palumbo, S Vincent Rajkumar, Jesus F San Miguel, et al.
Haematologica
|
October 4, 2015
European Myeloma Network guidelines for the management of multiple myeloma-related complications
Evangelos Terpos, Martina Kleber, Monika Engelhardt, et al.
Haematologica
|
April 16, 2016
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Katja C Weisel, Meletios A Dimopoulos, Philippe Moreau, et al.
Seminars in Hematology
|
May 16, 2025
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors
Jorge J Castillo, Francesco Autore, Neil L Berinstein, et al.
Seminars in Hematology
|
May 22, 2025
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathy
Shirley D'Sa, Jahanzaib Khwaja, Signy Chow, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 2, 2011
Prognostication of the high-risk WM patient
Efstathios Kastritis, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, et al.
Blood Advances
|
October 25, 2019
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone
Efstathios Kastritis, Ioanna Dialoupi, Maria Gavriatopoulou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 4, 2023
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
BMC Medicine
|
February 2, 2011
A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study
Christos A Papadimitriou, Pavlos Papakostas, Maria Karina, et al.
Hemasphere
|
August 29, 2025
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network
Grigoris Gerotziafas, Despina Fotiou, Inger Nijhof, et al.
Page
of 66